Wall Street Zen Upgrades Inovio Pharmaceuticals (NASDAQ:INO) to Hold

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on the company. Piper Sandler restated an “overweight” rating and set a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $6.75.

Inovio Pharmaceuticals Price Performance

Shares of Inovio Pharmaceuticals stock opened at $1.66 on Friday. The firm has a market cap of $110.77 million, a P/E ratio of -0.99 and a beta of 1.70. The firm has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $2.05. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.68. The firm had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.33 million. On average, sell-side analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. Caitong International Asset Management Co. Ltd boosted its holdings in Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 18,160 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the period. Focus Partners Wealth bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $33,000. GSA Capital Partners LLP raised its position in shares of Inovio Pharmaceuticals by 3.8% in the 4th quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 16,724 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at approximately $64,000. Institutional investors own 26.79% of the company’s stock.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.